Previous 10 | Next 10 |
The following slide deck was published by Molecular Templates, Inc. in conjunction with this event. For further details see: Molecular Templates (MTEM) presents at 2021 Oppenheimer Healthcare Conference
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...
AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which a...
AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, en...
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineer...
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which ar...
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sander...
Molecular Templates (MTEM): Q1 GAAP EPS of $0.51 beats by $0.26.Revenue of $3.22M (-22.2% Y/Y) misses by $31.93M.Press Release For further details see: Molecular Templates EPS beats by $0.26, misses on revenue
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, eng...
Molecular Templates ([[MTEM]] +9.5%) has posted its best one-day gain since December after Bank of America initiated the coverage on the stock with a buy rating and a price target of $12.00 per share indicating a premium of ~50.8% to yesterday’s close.The firm calls the company’...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...